Clinical significance of some genetic polymorphisms of cytochrome P-450: Family CYP1 and subfamilies CYP2A, CYP2B and CYP2C;Kliniczne znaczenie polimorfizmu wybranych genów cytochromu P-450: Rodziny CYP1, podrodziny CYP2A, CYP2B oraz CYP2C

Polski Merkuriusz Lekarski

Volumn 26, Issue 153, 2009, Pages 248-252

  Wojtczak, A ^a   Skretkowicz J ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Clinical consequences; Cytochrome P 450; Genetic polymorphism

Indexed keywords

CYCLOPHILIN; CYTOCHROME P 450 CYP1B1; CYTOCHROME P 450 CYP2C SUBFAMILY; CYTOCHROME P-450 CYP1B1; CYTOCHROME P-450 CYP2C SUBFAMILY; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 2B1; PPIG PROTEIN, HUMAN; STEROID HORMONE 7 ALPHA HYDROXYLASE; STEROID HORMONE 7-ALPHA-HYDROXYLASE; STEROID MONOOXYGENASE; UNSPECIFIC MONOOXYGENASE; XENOBIOTIC AGENT;

ARTICLE; BIOTRANSFORMATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; PHARMACOGENETICS;

ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CYCLOPHILINS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2B1; CYTOCHROME P-450 ENZYME SYSTEM; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; STEROID HYDROXYLASES; XENOBIOTICS;

EID: 64549123418     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Ambrosone C.B., Freudenheim J.L., Graham S. i wsp.: Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer. Res., 1995, 55, 3483.
2. Blanco G., Martinez C., Ladero J.M. i wsp.: Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. Pharmacogenetics & Genomics, 2008, 18, 37.
3. Cussenot O., Azzouzi A.R., Nicolaiew N. i wsp.: Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. J. Clin. Oncol., 2007, 25, 3596.
4. Daly A.K., Aithal G.P., Leathart J.B. i wsp.: Genetic susceptibility to diclo-fenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology, 2007, 132, 272.
5. Ferguson R.J., de Morais S.M., Benhamou S. i wsp.: A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J. Pharmacol. Exp. Ther., 1998, 284, 356.
6. Furuta T., Ohashi K., Kamata T. i wsp.: Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann. Intern. Med., 1998, 129, 1027.
7. Gawrońska-Szklarz B.: Polimorfizm genów enzymów biora̧cych udział w metabolizmie leków. Probl. Ter. Monit., 2000, 11, 14.
8. Gullstén H., Agundez J.A.G., Benitez J. i wsp.: CYP2A6 gene polymorphism and risk of liver cancer and cirrhosis. Pharmacogenetics, 1997, 7, 247.
9. Hailing J., Petersen M.S., Damkier P. i wsp.: Polymorphism of CYP2D6, CYP2C19, CYP2C9, CYP2C8 in the Faroese population. Eur. J. Clin. Pharmacol., 2005, 61, 491.
10. Higashi M.K., Veenstra D.L., Kondo L.M. i wsp.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. J. Am. Med. Assoc., 2002, 287, 1690.
11. Kirchheiner J., Seeringer A.: Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim. Biophys. Acta, 2007, 1770, 489.
12. Lang T., Klein K., Fischer J. i wsp.: Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics, 2001, 11, 399.
13. Li D., Jiao L., Li Y. i wsp.: Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis, 2006, 27, 103.
14. McKinnon R.A., Evans A.M.: Cytochrome P450. Clinically Significant Drug Interactions. Aust. J. Hosp. Pharm., 2000, 30, 146.
15. Melki R., Colomb E., Lefort N. i wsp.: CYP1B1 mutations in French patients with early-onset primary open-angle glaucoma. J. Med. Genet., 2004, 41, 647.
16. Obase Y., Shimoda T., Kawano T. i wsp.: Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with asthma. Clin. Pharmacol. Ther., 2003, 73, 468.
17. Paraskevaidis A., Drakoulis N., Roots I. i wsp.: Polymorphisms in the human cytochrome P-450 1A1 gene (CYP1A1) as a factor for developing acne. Dermatology, 1998, 196, 171.
18. Puga A., Nebert D., McKinnon R. i wsp.: Genetic polymorphisms in human drugmetabolizing enzymes: potential uses of reverse genetics to identify genes of toxicological relevance. Crit. Rev. Toxicol.: 1997, 27, 199.
19. Raunio H., Rautio A., Gullstén H. i wsp.: Polymorphisms of CYP2A6 and its practical consequences. Br. Journal. Clin. Pharmacol., 2001, 52, 357.
20. Roman R.: P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev., 2001, 82, 131.
21. Rudaś T., Droździk M.: Polimorfizm genetyczny w optymalizacji leczenia reumatoidalnego zapalenia stawów. Farm. Pol., 2006, 62, 964.
22. Scordo M.G., Aklillu E., Yasar U. i wsp.: Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population, Br. J. Clin. Pharmacol., 2001, 52, 447.
23. Siemińska A.: Genetyczne uwarunkowania uzależnienia od tytoniu. Alergia Astma Immunologia, 2005, 10, 69.
24. Skrȩtkowicz J., Rychlik-Sych M.: Polimorfizm cytochromu P-450. Farm. Pol., 2008, 64,61.
25. Sobjanek M., Zabtotna M., Sokoł owska-Wojdył o M i wsp.: Zwia̧zek polimorfizmu genu cytochromu P-450 1A1 (CYP1A1) z tra̧dzikiem pospolitym - wyniki wstȩpne. Post. Dermatol. Alergol., 2007, 24, 69.
26. Tanaka M., Ohkubo T., Otani K. i wsp.: Metabolic disposition of pantopra-zole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxyla-tion phenotype and genotype. Clin. Pharmacol. Ther., 1997, 62, 619.
27. Tassies D., Freire C., Pijoan J. i wsp.: Pharmacogenetics of acenoco-umarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica, 2002, 87, 1185.
28. Totah R.A., Rettie A.E.: Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin. Pharmacol. Ther., 2005, 77, 341.
29. Vijayalakshmi K., Vettriselvi V., Krishnan M. i wsp.: Cytochrome P-4501A1 gene variants as susceptibility marker for prostate cancer. Cancer Bio-mark., 2005, 1, 251.
30. Visser L.E., van Schaik R.H., van Vliet M. i wsp.: The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb. Haemost., 2004, 92, 61.
31. Vistisen K., Lofl S., Olsen J.H. i wsp.: Low CYP1A2 activity associated with testicular cancer. Carcinogenesis, 2004, 25, 923.
32. Walle T., Walle U.K.: Novel methoxylated flavone inhibitors of cytochrome P450 1B1 in SCC-9 human oral cancer cells. J. Pharm. Pharmacol., 2007, 59, 857.
33. Wan J., Xia H., He N. i wsp.: The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. Br. J. Clin. Pharmacol., 1996, 42, 471.
34. van der Weide J., Steijns L.S., van Weelden M.J. i wsp.: The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics, 2001, 11, 287.
35. Wenzlaff A.S., Cote M.L., Bock C.H. i wsp.: CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study. Carcinogenesis, 2005, 26, 2207.
36. Yang C.X., Matsuo K., Wang Z.M., Tajima K.: Phase I/II enzyme gene polymorphisms and esophageal cancer risk: a meta-analysis of the literature. World J. Gastroenterol., 2005, 11, 2531.
37. Yasar U., Bennet A.M., Eliasson E. i wsp.: Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics, 2003, 13, 715.
38. Yasar U., Forslund-Bergengren C., Tybring G. i wsp.: Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin. Pharmacol. Ther., 2002, 71, 89.
39. Zhang Y., Si D., Chen X. i wsp.: Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects. Br. J. Clin. Pharmacology, 2007, 64, 67.
40. Zhu-Ge J., Yu Y.: Enzyme activity analysis of CYP2C18 with exon 5 skip-ped1. Acta Pharmacol. Sin., 2004, 25, 1065.